High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations

Brodská, Barbora; Otevřelová, Petra; Šálek, Cyril; Fuchs, Ota; Gašová, Zdenka; Kuželová, Kateřina

doi:10.3390/ijms20112823

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations

and

Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic

Author to whom correspondence should be addressed.

Int. J. Mol. Sci. 2019, 20(11), 2823; https://doi.org/10.3390/ijms20112823

Received: 30 April 2019 / Revised: 31 May 2019 / Accepted: 6 June 2019 / Published: 10 June 2019

(This article belongs to the Special Issue PD-L1, A Master Regulator of Immunity)

View Full-Text Download PDF

Browse Figures

Review Reports Citation Export

Abstract

Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored, and the knowledge in this area is mostly limited to lymphomas. However, several studies indicated that PD-L1 is also overexpressed in myeloid malignancies. Successful treatment of the acute myeloid leukemia (AML) is likely associated with elimination of the residual disease by the immune system, and possible involvement of PD-L1 in this process remains to be elucidated. We analyzed PD-L1 expression on AML primary cells by flow cytometry and, in parallel, transcript levels were determined for the transcription variants v1 and v2. The ratio of v1/v2 cDNA correlated with the surface protein amount, and high v1/v2 levels were associated with worse overall survival (p = 0.0045). The prognostic impact of PD-L1 was limited to AML with mutated nucleophosmin and concomitant internal tandem duplications in the FLT3 gene (p less than 0.0001 for this particular AML subgroup). View Full-Text

Keywords: leukemia; AML; FLT3-ITD; NPM1; PD-L1 transcript; PD-1; CD34

▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Brodská, B.; Otevřelová, P.; Šálek, C.; Fuchs, O.; Gašová, Z.; Kuželová, K. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. Int. J. Mol. Sci. 2019, 20, 2823. https://doi.org/10.3390/ijms20112823

AMA Style

Brodská B, Otevřelová P, Šálek C, Fuchs O, Gašová Z, Kuželová K. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. International Journal of Molecular Sciences. 2019; 20(11):2823. https://doi.org/10.3390/ijms20112823

Chicago/Turabian Style

Brodská, Barbora, Petra Otevřelová, Cyril Šálek, Ota Fuchs, Zdenka Gašová, and Kateřina Kuželová. 2019. "High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations" International Journal of Molecular Sciences 20, no. 11: 2823. https://doi.org/10.3390/ijms20112823

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI